Amezosvatein Antigen Low Dose Arm B for herpes zoster

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Feb 2022: Trial started, NCT05304351
  2. 31 Mar 2022: Trial registered, NCT05304351

The trials

NCT05304351: Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

State
Under way
Phase
Phase 2
People
1,516 taking part
Started
2 Feb 2022
Primary completion
30 Jun 2026
Arms
Arm B
Results
None posted
  1. 2 Feb 2022: Trial started
  2. 31 Mar 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.